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ABSTRACT : Twenty patients with bone metastasis following surgery for recurrent 
breast cancer were clinically evaluated in analysis of clinicopathologic aspect in 
comparison with those with metastases in other organ. It is more likely that bone 
metastasis occurs in younger patients as compared with other organ metastasis. 
   However, there were no certain clinical patterns of patients with bone metastasis 
including the survival time, as compared with those with other organ metastasis. 
   In this series, ER and PgR failed to measure and to elucidate the effect of hormore 
therapy because a subject includes parts of patients prior to development of ER and PgR 
measurement. 
   In conclusion, there were no clinicopathologic features in patients with bone metastasis 
following surgical treatment of breast cancer except for occurrence in younger patients.
       INTRODUCTION 
 It is frequent to encounter in patients with 
recurrent breast cancer in accordance with an 
increasing number of surgical patients. In case 
of recurrent breast cancer, it is characteristic 
of a long-term clinical course with a reflection 
of slow growth of recurrent tumors. Therefore, 
it is possible to select an appropriate therapy 
among various kinds of therapeutic approaches. 
 Recurrence of breast cancer is divided into 
the two categories, that is, distant metastasis 
into the bone, the lung, the liver and the brain, 
and local recurrence in the thoracic wall and 
regional lymph nodes. 
 Advances in detecting procedures and devel-
opment of various kinds of instruments made 
it possible to detect recurrent breast cancer in 
early stage and to accurrately assess the sites 
of recurrence. 
 In this study, patients with bone metastasis
from breast cancer were clinically reviewed in 
terms of the prognosis and the treatment to 
certify the effect of prolonging the survival time.
          PATIENTS 
 Twenty patients with bone metastasis were 
subject to this study as compared with 73 
patients who had recurrence from breast cancer 
except in the bone. 
 Table 1 showed the result of comparative 
study in recurrent breast cancer between the 
bone and other organs in relation to T factor. 
Recurrent patients included advanced disease 
stages as shown in Table 2 and most had the 
tumor size of T2 and more. As indicated in Table 
3, the disease stage in patients with recurrent 
breast cancer is relatively progressed although 
there is no significant difference between pa-
tients with bone metastasis and with metastases 
in other organ. Detection of bone metastasis 
was a symptome of pain in the majority of
Fig. 1. Survival rates according to metastatic sites 
       in breast cancer
Table 1. No. of cases according to T factors in 
         recurrent breast cancers 
          T1 T2 T3 T4 Total 
bone meta. 2(10.0) 11(55.0) 6(30.0) 1( 5.0) 20 
other 10(13.7) 28(38.4) 19(26.0) 16(21.9) 73 
 Total 12(12.9) 39(41.9) 25(26.9) 17(18.3) 93 
                             ( ):%
Table 2. No. of cases according to Tnm-stage in 
         recurrent breast cancers 
          I II Ill-a III-b IV Total 
bone meta. 2(10.0) 11(55.0) 4(20.0) 1( 5.0) 2(10.0) 20 
other 7( 9.6) 23(31.5) 17(23.3) 13(17.8) 13(17.8) 73 
 Total 9( 9.7) 34(36.6) 21(22.6) 14(15.1) 15(16.1) 93
Table 3. No. of cases according to Tnm-stage in 
         recurrent breast cancers 
          I II III IV Total 
bone meta. 6(30.0) 7(35.0) 4(20.0) 3(15.0) 20 
other 18(24.7) 17(23.3) 13(17.8) 25(34.2) 73 
 Total 24(25.8) 24(25.8) 17(18.3) 28(30.1) 93
Table 4. No. of cases according to age in age in 
         recurrent breast cancers 
         20-29 30-39 40-49 50-59 60-69 70-79 Total 
bone meta. 0 4(20.0) 8(40.0) 4(20.0) 4(20.0) 0 20 
other 2(2.7) 11(15.1) 21(28.8) 27(37.0) 10(13.7) 2(2.7) 73 
 Total 2(2.2) 15(16.1) 29(31.2) 31(33.3) 14(15.1) 2(2.2) 93 
                             ( ):%
Table 5. No. of cases according to n factors in 
         recurrent breast cancers 
            nO nla nll n2,3 Total 
bone meta. 6(30.0) 5(25.0) 6(30.0) 3(15.0) 20 
other 21(28.8) 12(16.4) 16(21.9) 23(31.5) 73 
 Total 27(29.0) 17(18.3) 22(23.7) 26(27.9) 93
Table 6. No. of cases according to histological 
         classification in recurrent breast cancers 
           Papillo. Solid-t. Scirrh. Specia. Total 
bone meta. 5(25.0) 9(45.0) 5(25.0) 1(5.0)''` 20 
other 24(33.8) 25(35.2) 19(26.8) 2(2.8)'* 71 
 Total 29(31.9) 34(37.4) 24(26.4) 3(3.3) 91 
   ~= Medullary carcinoma ( ) % 
        Invasive lobular carcinoma 
Papillo.: Papillotubular carcinoma, Solid-t.: Solid-
tubular carcinoma, Scirrh.: Scirrhous carcinoma, 
Specia.: Special types.
Table 7. No. of cases according to operation in 
         recurrent breast cancers 
           Modifie. Standar. Extend. Super. Total 
bone meta. 2(10.0) 5(25.0) 12(60.0) 1(5.0) 20 
other 21(29.2) 15(20.5) 32(43.8) 4(5.5) 72 
 Total 23(25.0) 20(21.7) 44(47.8) 5(5.4) 92 
Modifie.: modified radical mastectomy, Standar.: 
standard radical mastectomy, Extend.: extended 
radical mastectomy, Super.: super extended radical 
mastectomy
patients with high serum calcium levels. Con-
firmation was made by x-Ray film which dis-
played bone destruction of mainly osteolytic 
shadow. 
 According to patient's ages, patients with 
bone metastasis distributed in younger age al-
though the ages of those with metastases in 
other organ ranged from 40 to 59 years old as 
shown in Table 4. 
 As for node metastasis, two thirds of patients 
affected the nodes, in particular, in the axillar 
region as shown in Table 5. 
 In analysis of histologic types, there was no 
definitive difference in histologic types between 
the patients with bone metastasis and with 
metastases in other organ as indicated in Table
6. 
 The operative procedures used were shown 
in Table 6 and 7. There was no particular in 
patients with bone metastasis when compar-
ed with metastases in other organs. However, 
extended radical mastectomy is more often used 
for patients with recurrent breast cancer. 
 Figure 7 showed the survival curves between 
patients with bone metastasis and with metas-
tases in other organ. There was not significant 
difference in the survival curve between patients 
with bone metastasis and with metastases in 
other organ. The disease free interval in 
patients with bone metastasis ranged from 10 
months to 61 months with an average of 27.6 
months, indicating not significant difference 
between the two group patients. 
         DISCUSSION
 The measurement of the levels of tumor mark-
er is now in clinical use to detect recurrence in 
early stage. Various tumor markers such as 
CEA, CA15-3, TPA, IAP, BMG, Ft, AFP is now 
clinically available for detection of recurrence. 
Anticancer drugs play a key role in the treat-
ment of recurrent breast cancer. In addition, 
anticancer agents such as CA, CAF and CAPT 
were used in combination with hormone thera-
pyl, z> 
 Recently, combined hormone therapy of 
choice is now prevalent to obtain complete 
remission in sequence of tamoxifen and MPA3'. 
In fact, Chemo-endocrine therapy is effective in 
prolonging the survival time of patients with 
recurrent and/or advanced breast cancer. 
 In this series, clinical features of recurrent 
breast cancer were clinically evaluated. There 
was no special pattern of patients with bone 
metastasis as compared with those having 
metastases in other organ in terms of the disease 
stage and the survival time. However, the ages 
of patients with bone metastasis were somewhat 
younger as compared with those metastasizing 
to other organ. Therefore, the hormone thera-
py in combination with anticancer drugs is 
mandatory for the treatment of ER and PgR 
positive patients with bone metastasis. 
 It is reported that the hormone therapy is 
effective for 50 to 60 per cent of positive ER
patients4' 5). On the contrary, even 10 per cent 
of ER negative patients is effective for the 
hormone therapy". 
 For the reasons of no effect of the hormone 
therapy in ER positive patients, the levels of ER 
are not uniform in all breast cancer cells with 
inter-site variation. Some investigators6'7' clari-
fied that histologically high intensity of malig-
nancy decreases ER and PgR positive rates. 
 It is accepted that according to increasing 
intensity of histologic cell malignancy, ER and 
PgR positive rates are reduced. In addition, it 
is reported that ER positive breast cancer is 
particularly prone to occurrence of bone and 
skin metastases. 
 On the other hand, it is said that ER negative 
breast cancers are more likely to metastasize 
to the liver'. 
 As for PgR positive breast cancers, these have 
a prolonged disease free interval as compared 
with PgR negative one". However, Sutton") and 
Thorpe1) et al clarified that the disease free 
interval is unrelatd to PgR positive rates. 
 It is no doubt that recurent breast cancer cells 
pose extensively malignant behavior with a high 
intensity of cell malignancy in view of histology. 
The more the intensity of cell malignancy 
increases, the more ER and PgR positive rates 
are lowered. This implies that the effect of the 
hormone therapy for recurrent breast cancer is 
reduced in accordance with the extension of 
recurrent breast cancer. It is generally accepted 
that the hormone therapy is preceded by 
chemotherapy to enhance the effects of valid 
chemoendocrine therapy for recurrent breast 
cancer. 
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